SB02024

SB02024 is a potent and orally active VPS34 inhibitor. SB02024 inhibits Vps34 kinase activity. SB02024 induces CCL5 and CXCL10 via STAT1/IRF7. SB02024 shows anticancer activity[1][2][3].

Product Specifications

CAS Number

[2126737-28-6]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

CXCR; PI3K; STAT

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation; JAK/STAT Signaling; PI3K/Akt/mTOR; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/sb02024.html

Purity

99.70

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C1C=C(N2[C@H](C)COCC2)C=C(N3[C@@H](C(F)(F)F)CCCC3)N1

Molecular Formula

C16H22F3N3O2

Molecular Weight

345.36

Precautions

H302, H315, H319, H335

References & Citations

[1]Noman MZ, et al. Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti-PD-1/PD-L1 immunotherapy. Sci Adv. 2020 Apr 29;6 (18) :eaax7881.|[2]Yu Y, et al. Combining VPS34 inhibitors with STING agonists enhances type I interferon signaling and anti-tumor efficacy. Mol Oncol. 2024 Mar 20.|[3]Bassam Claude JANJI, et al. Biomarker. Patent WO2020008046 A1.